Patent ID: 8404848

Claim:
A method for treating multiple sclerosis, cerebral trauma, epilepsy, osteoporosis, Parkinson's disease, Alzheimer's disease, tauopathy, schizophrenia, depression, or substance dependence in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound of formula (I): wherein: X is phenyl optionally substituted by one or more groups chosen, independently of one another, from the group consisting of halogen, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkoxy, and NRaRb; R 1 is hydrogen, halogen, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkoxy, amino or NRcRd, wherein the alkyl and alkoxy groups are optionally substituted by one or more halogen, hydroxyl, amino, or (C 1 -C 6 )alkoxy; R 2 is hydrogen, (C 1 -C 6 )alkyl optionally substituted by one or more groups chosen, independently of one another, from the group consisting of hydroxyl, halogen, amino, NRaRb and phenyl, (C 1 -C 6 )alkoxy optionally substituted by one or more groups chosen, independently of one another, from the group consisting of hydroxyl, halogen, amino, and NRaRb, (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkoxy, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, —CO—R 5 , —CO—NR 6 R 7 , —CO—O—R 8 , —NR 9 —CO—R 10 , —NR 11 R 12 , halogen, cyano, or phenyl optionally substituted by one or more groups chosen, independently of one another, from the group consisting of halogen, (C 1 -C 6 )alkoxy, NRaRb, —CO—R 5 , —CO—NR 6 R 7 , —CO—O—R 8 , (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl-(C 1 -C 6 )alkoxy, and (C 1 -C 6 )alkyl optionally substituted by one or more hydroxyl or NRaRb; R 3 is hydrogen, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy or halogen; R 4 is hydrogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy or fluorine; R 5 is hydrogen, phenyl or (C 1 -C 6 )alkyl; R 6 and R 7 are independently hydrogen or (C 1 -C 6 )alkyl, or R 6 and R 7 , taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring optionally including another heteroatom chosen from the group consisting of N, O and S; R 8 is (C 1 -C 6 )alkyl; R 9 and R 10 are independently hydrogen or (C 1 -C 6 )alkyl; R 11 and R 12 are independently (C 1 -C 6 )alkyl, or R 11 and R 12 , taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring optionally including another heteroatom chosen from the group consisting of N, O and S; Ra and Rb are independently hydrogen or (C 1 -C 6 )alkyl, or Ra and Rb, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring; Rc is hydrogen; and Rd is (C 1 -C 6 )alkyl; provided that: at least one of R 1 , R 2 , R 3 and R 4 is other than hydrogen, when R 3 is methyl, then X is unsubstituted, when R 1 is methyl, then X is unsubstituted, and when R 2 is chlorine, then X is not a para-fluorophenyl; or a pharmaceutically acceptable salt thereof.